Axel Dalhoff

Summary

Affiliation: Bayer AG
Country: Germany

Publications

  1. ncbi Pharmacodynamics of fluoroquinolones
    A Dalhoff
    Bayer AG, Pharma Research Centre, Wuppertal, Germany
    J Antimicrob Chemother 43:51-9. 1999
  2. ncbi Beta-lactamase stability of faropenem
    A Dalhoff
    Bayer AG Pharma Research Center, Wuppertal Germany
    Chemotherapy 49:229-36. 2003
  3. ncbi Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria
    A Dalhoff
    Pharma Research Center, Bayer AG, Wuppertal, Germany
    Chemotherapy 49:172-83. 2003
  4. ncbi The art of fusion: from penams and cephems to penems
    Axel Dalhoff
    Pharma Research Center, Bayer AG Wuppertal, Wuppertal, Germany
    Chemotherapy 49:105-20. 2003
  5. ncbi Immunomodulatory effects of quinolones
    Axel Dalhoff
    Institute for Medical Microbiology and Virology, Universitatsklinikum Schleswig Holstein, Campus Kiel, Germany
    Lancet Infect Dis 3:359-71. 2003
  6. ncbi In vitro antibacterial activity and pharmacodynamics of new quinolones
    A Dalhoff
    Institute for Medical Microbiology and Virology, Universitatsklinikum Schleswig Holstein, Brunswiker Strasse 4, 24105 Kiel, Germany
    Eur J Clin Microbiol Infect Dis 22:203-21. 2003
  7. ncbi Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity
    A Dalhoff
    Research and Development Centre, Bayer AG, Pharma Research Center Wuppertal, PH PD SDD AI, Building 402, Aprather Weg 18, D 42113 Wuppertal, Germany
    Clin Infect Dis 32:S22-9. 2001
  8. ncbi Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118
    A Dalhoff
    Bayer AG, Pharma Research Center Wuppertal, PH PD SDD AI, Building 402, Aprather Weg 18, D 42113 Wuppertal, Germany
    Clin Infect Dis 32:S16-22. 2001
  9. doi Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones
    Axel Dalhoff
    University Hospital Schleswig Holstein, Campus Kiel, Institute for Infection Medicine, Brunswiker Str 4, 24105 Kiel, Germany
    Int J Antimicrob Agents 36:216-21. 2010
  10. ncbi Redefining penems
    Axel Dalhoff
    University Hospital Schleswig Holstein, Campus Kiel, Institute for Infection Medicine, Brunswiker Str 4, D 24105 Kiel, Germany
    Biochem Pharmacol 71:1085-95. 2006

Collaborators

Detail Information

Publications15

  1. ncbi Pharmacodynamics of fluoroquinolones
    A Dalhoff
    Bayer AG, Pharma Research Centre, Wuppertal, Germany
    J Antimicrob Chemother 43:51-9. 1999
    ..Thus, the in-vitro and in-vivo pharmacodynamic models used in this study established that moxifloxacin was highly effective against both gram-negative and gram-positive bacteria...
  2. ncbi Beta-lactamase stability of faropenem
    A Dalhoff
    Bayer AG Pharma Research Center, Wuppertal Germany
    Chemotherapy 49:229-36. 2003
    ..In conclusion, FAR is characterized by pronounced BLA stability compared to other cephalosporins and imipenem. Furthermore, a lower propensity for resistance development with FAR as compared to cephalosporins was observed...
  3. ncbi Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria
    A Dalhoff
    Pharma Research Center, Bayer AG, Wuppertal, Germany
    Chemotherapy 49:172-83. 2003
    ..Thus, the high binding affinities of faropenem to PBPs from gram-negative and gram-positive bacteria are mirrored by its pronounced and concentration-dependent bactericidal effect...
  4. ncbi The art of fusion: from penams and cephems to penems
    Axel Dalhoff
    Pharma Research Center, Bayer AG Wuppertal, Wuppertal, Germany
    Chemotherapy 49:105-20. 2003
    ..aeruginosa due to their improved binding affinity to both wild-type and modified low-affinity penicillin binding proteins. The development of these agents may offer therapeutic alternatives for the management of infections...
  5. ncbi Immunomodulatory effects of quinolones
    Axel Dalhoff
    Institute for Medical Microbiology and Virology, Universitatsklinikum Schleswig Holstein, Campus Kiel, Germany
    Lancet Infect Dis 3:359-71. 2003
    ....
  6. ncbi In vitro antibacterial activity and pharmacodynamics of new quinolones
    A Dalhoff
    Institute for Medical Microbiology and Virology, Universitatsklinikum Schleswig Holstein, Brunswiker Strasse 4, 24105 Kiel, Germany
    Eur J Clin Microbiol Infect Dis 22:203-21. 2003
    ....
  7. ncbi Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity
    A Dalhoff
    Research and Development Centre, Bayer AG, Pharma Research Center Wuppertal, PH PD SDD AI, Building 402, Aprather Weg 18, D 42113 Wuppertal, Germany
    Clin Infect Dis 32:S22-9. 2001
    ..We review the preclinical data corroborated by the available clinical experience to demonstrate moxifloxacin's activity against S. pneumoniae strains, irrespective of penicillin susceptibility...
  8. ncbi Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118
    A Dalhoff
    Bayer AG, Pharma Research Center Wuppertal, PH PD SDD AI, Building 402, Aprather Weg 18, D 42113 Wuppertal, Germany
    Clin Infect Dis 32:S16-22. 2001
    ..Thus, as the C-8 moiety was the only difference, the 8-methoxy group on moxifloxacin appeared to significantly lower the propensity for quinolone resistance development...
  9. doi Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones
    Axel Dalhoff
    University Hospital Schleswig Holstein, Campus Kiel, Institute for Infection Medicine, Brunswiker Str 4, 24105 Kiel, Germany
    Int J Antimicrob Agents 36:216-21. 2010
    ..Thus, fluoroquinolones exert a dichotomous MRSA-selective potential in heteroresistant MRSA...
  10. ncbi Redefining penems
    Axel Dalhoff
    University Hospital Schleswig Holstein, Campus Kiel, Institute for Infection Medicine, Brunswiker Str 4, D 24105 Kiel, Germany
    Biochem Pharmacol 71:1085-95. 2006
    ....
  11. pmc Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine
    Axel Dalhoff
    University Hospital Schleswig Holstein, Campus Kiel, Institute for Infection Medicine, Brunswiker Str 4, D 24105 Kiel, Germany
    Antimicrob Agents Chemother 55:1814-8. 2011
    ..Ciprofloxacin MICs increased and bactericidal activity decreased strain dependently in acidic CAMHB and particularly in artificial urine...
  12. ncbi Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose
    Florian M E Wagenlehner
    Department of Urology, St Elisabeth Hospital, Straubing, Germany
    Int J Antimicrob Agents 27:7-14. 2006
    ..Therefore, it can be assumed that the two doses investigated can be considered equivalent for the treatment of UTI...
  13. pmc Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge
    Martina Ulrich
    Institute of Medical Microbiology and Hygiene, Universitatsklinikum Tubingen, Wilhelmstrasse 31, D 72074 Tubingen, Germany
    Antimicrob Agents Chemother 49:5119-22. 2005
    ..Moxifloxacin and azithromycin effectively killed intracellular S. pneumoniae strains and protected respiratory epithelial cells significantly even when given 6 h after S. pneumoniae challenge. Amoxicillin was less effective...
  14. pmc Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin
    Alison K Meagher
    CPL Associates, LLC, Amherst, New York, USA
    Antimicrob Agents Chemother 48:2061-8. 2004
    ..75 and 2.49, respectively; and those for XR were 4.54 and 3.13, respectively. The mathematical model explained the differences in bacterial killing rate for two regimens with identical AUC/MIC ratios...
  15. ncbi Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing?
    Lance R Peterson
    Evanston Northwestern Healthcare Research Institute, Evanston Northwestern Healthcare, Division of Microbiology, Department of Pathology and Laboratory Medicine, Northwestern University, Evanston, IL 60201, USA
    J Antimicrob Chemother 53:902-5. 2004
    ..This diagnostic advance could preserve the utility of antimicrobial agents well into the future for the benefit of all people...